Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials

Faldaprevir is a potent once-daily (q.d.) hepatitis C virus (HCV) NS3/4A protease inhibitor. The STARTVerso1 and STARTVerso2 phase 3 studies evaluated faldaprevir plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in treatment-naïve patients with chronic HCV genotype-1 infection. Patients were random...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of hepatology 2016-05, Vol.15 (3), p.333
Hauptverfasser:	Jensen, Donald M, Asselah, Tarik, Dieterich, Douglas, Foster, Graham R, Sulkowski, Mark S, Zeuzem, Stefan, Mantry, Parvez, Yoshida, Eric M, Moreno, Christophe, Ouzan, Denis, Wright, Mark, Morano, Luis E, Buynak, Robert, Bourlière, Marc, Hassanein, Tarek, Nishiguchi, Shuhei, Kao, Jia-Horng, Omata, Masao, Paik, Seung W, Wong, David K, Tam, Edward, Kaita, Kelly, Feinman, S Victor, Stern, Jerry O, Scherer, Joseph, Quinson, Anne-Marie, Voss, Florian, Gallivan, John-Paul, Böcher, Wulf O, Ferenci, Peter
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!